COYA 302
Asset
Combines low-dose interleukin-2 and an abatacept biosimilar to enhance regulatory T-cell function and suppress inflammatory immune activation.
- Stage
- Phase 2
- Modality
- Protein or enzyme
- Target
- CD80
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Amyotrophic lateral sclerosis
Phase 2, Active not recruiting, NCT07161999, clinicaltrials.gov, 16 Oct 2026
In the full profile
- Targets and what it contains8
- Owner and partners1
- Trials1
- Evidence for its targets8
- Competitors7
- Aging relevance2
Every asset’s record: target, stage, trials and the evidence behind it.